Natalie Arnold/LinkedIn
Jan 25, 2026, 12:17
Natalie Arnold on 11 Clinical Trials That Will Shape Medicine in 2026
Natalie Arnold, Preventive Cardiologist at University Heart and Vascular Center Hamburg, shared on LinkedIn:
”“What does the coming day hold (for me)?”
(AS Pushkin, Eugene Onegin)
Nature Medicine recently spotlighted 11 clinical trials that may shape medicine in 2026.
Two of them align directly with my research focus in cardiovascular prevention:
• Low-grade inflammation: IL-6 inhibition with ziltivekimab
• Lipoprotein (a): pelacarsen for patients with elevated Lp(a)
2026 may be a key year for turning “residual risk” biology into therapies that improve clinical outcomes.”
Read the full article here.
Article: Eleven clinical trials that will shape medicine in 2026
Author: Mike May
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jun 23, 2026, 18:17What Every ITP Patient Wants to Know – ITP Support Association
-
Jun 23, 2026, 18:13Ahsan Fareed: Exploring Heart Failure Readmissions in Iron Deficiency Anemia
-
Jun 23, 2026, 18:09Swarnava Roy: Key Findings on Stress Erythropoiesis and Mitochondrial Retention in RBCs
-
Jun 23, 2026, 17:40Hossam El Benawi: How do We Predict Recurrence Post LVT Resoultion?
-
Jun 23, 2026, 17:39Nicolas Gendron: Do We Really Need All These Hemostasis Tests in Patients on DOACs?
-
Jun 23, 2026, 17:33Maité Mulkers: Time is Brain, and One Reason is That a Thrombus Develops Over Time
-
Jun 23, 2026, 17:32Dhargam Aljebouri: Honoured to Be Part of the Young Professionals Breakfast at ISBT 2026
-
Jun 23, 2026, 17:27Dianne E. van der Wal: Phenotype and Activation of the Endothelium in ET at ISTH 2026